Dai­ichi Sankyo sweeps out Pieris drug, 5 oth­ers in a Q1 pipeline cleanup

Just a few days af­ter lin­ing up $57.5 mil­lion in near-term cash from a high-pro­file col­lab­o­ra­tion deal with As­traZeneca on its An­ti­calin plat­form, one of Pieris’ oth­er part­ners un­cer­e­mo­ni­ous­ly swept out one of their clin­i­cal-stage ther­a­pies in a Q1 pipeline cleanup.

DS-9001 was dropped by Dai­ichi Sankyo af­ter in­ves­ti­ga­tors re­viewed the da­ta they had on the Phase I ther­a­py tar­get­ing PC­SK9. Pieris $PIRS has been work­ing for years on en­gi­neer­ing pro­teins that are lighter and more ver­sa­tile than an­ti­bod­ies, so that they can work where an­ti­bod­ies find their en­try barred.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER